Skip to main content


Director, Division of Infectious Diseases at JHSOM
Amita Gupta

Departmental Affiliations

School of Medicine
Global Disease Epidemiology and Control

Contact Info

600 N. Wolfe Street, Phipps 540-B

Research Interests

Infectious diseases in India; HIV and malnutrition; TB cohorts in India; acute febrile illness; TB in pregnancy; TB preventive therapy trials in adults, children, pregnant women; MDR TB Clinical trials; preventive therapies; and treatments; observational cohort studies; Tuberculosis and HIV; India; Low and middle-income countries; Interactions of infectious and chronic diseases; TB biomarker research; Antimicrobial resistance; Maternal and child health; Pregnancy; pediatrics; adults; household contacts.

Experiences & Accomplishments
Johns Hopkins Bloomberg School of Public Health
Harvard Medical School

Dr. Gupta is the Florence Sabin Professor of Infectious Diseases and Director of the Division of Infectious Diseases at the Johns Hopkins School of Medicine, and she holds a joint appointment in the Department of International Health at the JH Bloomberg School of Public Health. She is board-certified in infectious diseases and is a practicing physician at Johns Hopkins Hospital. 

Dr. Gupta’s work focuses on international clinical research, public health, and education in infectious diseases, with specialties in HIV/AIDS, tuberculosis (TB), and antimicrobial resistant infections. Since 2003, her research has focused primarily on India, where she leads several JHU research collaborations. She has been awarded research grants from the NIH, CDC, UNITAID, and several philanthropic foundations to investigate infectious diseases of importance to India and beyond. She is a faculty member of the Center for Infectious Diseases in India, and is the founder and Faculty Steering Committee Co-chair of the Gupta-Klinsky India Institute (GKII). GKII brings together more than 165 faculty from across 7 Johns Hopkins University schools to collaborate with Indian institutions on research, programs, and policies that serve Indo-US national and global interests.   

She is an active clinical investigator in multi-country trials conducted by the Advancing Clinical Therapeutics Globally (ACTG) network and the International Maternal Pediatric Adolescent AIDS Trials network (IMPAACT), and she has served as protocol chair for high impact TB prevention studies that have resulted in publications in The New England Journal of Medicine and The Lancet.  

Dr. Gupta’s other scientific leadership positions include serving Vice-Chair for the IMPAACT TB Scientific Committee. She is US Chair for the Indo-US Vaccine Action Program-sponsored RePORT India TB research consortium, which is funded by the US National Institutes of Health (NIH) and the government of India, Department of Biotechnology since 2013. She also is a member of the global RePORT International Executive Committee, a multilateral global consortia for TB research, and Co-principal Investigator of the NIH-funded Johns Hopkins University Baltimore-India Clinical Trials Unit (JHUBI-CTU). She previously served on the Johns Hopkins Precision Medicine Center for Excellence for COVID-19, and in 2019, Dr. Gupta was appointed by the US Health and Human Services Secretary for a 4-year term to the NIAID Council, the chief advisory committee for National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health. In 2020, she was invited to the Governing Board of the Indo-U.S. Science & Technology Forum, and in 2023 was appointed to serve on the Association of American Universities’ Task Force on Expanding United States-India Partnerships. She is a Founder’s Circle member of Indiaspora. 

Dr. Gupta is an author of more than 250 peer-reviewed research publications and 7 book chapters on prevention and treatment of HIV, TB, and other infectious diseases, primarily in low- and middle-income settings. She has mentored more than 40 junior scientists in India and the US to run research studies and submit their own scientific findings to peer-reviewed publications. 

Dr. Gupta received an undergraduate degree from Massachusetts Institute of Technology (MIT) in Materials Science Engineering, a Doctor of Medicine from Harvard Medical School, and a Master of Health Sciences in clinical investigation from Johns Hopkins Bloomberg School of Public Health. She completed her internal medicine training at San Francisco General Hospital-University of California, San Francisco, followed by post-doctoral fellowships with the Epidemic Intelligence Service at the US Centers for Disease Control and Prevention (CDC, Foodborne and Diarrheal Diseases) and at the Johns Hopkins School of Medicine (Infectious Diseases). 

Honors & Awards

1991: MIT Women Studies Writing Prize “Women and AIDS in the United States: Unheard Voices”
1991: MIT Student Humanitarian Award
1991: Sigma Xi Research Honor Society
1993: Harvard Medical School Urban Health Fellowship
1996: Paul Dudley White & Andrew Sellard Traveling Fellowship
2000: IDSA Special Citation for Fellows-in-Training
2001: Reza Gandeji Award (UCSF resident award for medical ethics and compassionate patient care)
2002: Mackel Finalist, Epidemic Intelligence Service Conference, Centers for Disease Control and Prevention
2002: U.S. Public Health Service Award for Bioterrorism Surveillance Post 9/11
2002: U.S. Public Health Service Award for Foreign Duty Service (cholera in Micronesia)
2017: Invited Member, Women in Global Health Advisory Board, Cornell University
2007: Clinician Scientist Award, Johns Hopkins University School of Medicine
2018: Honored as one of “Hopkins Heroes,” Johns Hopkins School of Medicine
2019: Invited by US HHS Secretary to be a member of the NIAID National Advisory Allergy and Infectious Diseases Council
2020: Invited by US State Department and Indian government to serve on the Governing Board of the Indo-US Science and Technology Forum (IUSSTF)

2023: Appointed by the Association of American Universities to serve on the Task Force on Expanding United States-India Partnerships

2024: Member, WHO Working Group on Tuberculosis and Pregnancy 

2024: Member, WHO Guidelines Committee for Treatment of Drug-resistant Tuberculosis

Select Publications

Selected Publications

  • Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, Chipato T, Vhembo T, Stranix-Chibanda L, Onyango-Makumbi C, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Mave V, Rouzier V, Hesseling A, Shin K, Zimmer B, Costello D, Sterling TR, Chakhtoura N, Jean-Philippe P, Weinberg A. Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med. 2019 Oct 3;381(14):1333-1346. PMID: 31577875.

  • Krishnan S, Wu X, Kim S, McIntire K, Naini L, Hughes MD, Dawson R, Mave V, Gaikwad S, Sanchez J, Mendoza-Ticona A, Gonzales P, Comins K, Shenje J, Nerette Fontain S, Omozoarhe A, Mohapi L, Lalloo UG, Garcia Ferreira AC, Mugah C, Harrington M, Shah NS, Hesseling AC, Churchyard G, Swindells S, Gupta A; AIDS Clinical Trials Group (ACTG) A5300/International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) I2003 Protecting Households on Exposure to Newly Diagnosed Index Multidrug-resistant Tuberculosis Patients (PHOENIx) Feasibility Study Team. One-year incidence of tuberculosis infection and disease among household contacts of rifampin- and multi-drug resistant tuberculosis. Clin Infect Dis. 2023 May 25:ciad301. doi: 10.1093/cid/ciad301. Epub ahead of print. PMID: 37227925.  

  • Miner MD, Hatherill M, Mave V, Gray GE, Nachman S, Read SW, White RG, Hesseling A, Cobelens F, Patel S, Frick M, Bailey T, Seder R, Flynn J, Rengarajan J, Kaushal D, Hanekom W, Schmidt AC, Scriba TJ, Nemes E, Andersen-Nissen E, Landay A, Dorman SE, Aldrovandi G, Cranmer LM, Day CL, Garcia-Basteiro AL, Fiore-Gartland A, Mogg R, Kublin JG, Gupta A, Churchyard G. Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel. Lancet HIV. 2022 Nov;9(11):e791-e800. doi: 10.1016/S2352-3018(22)00255-7. Epub 2022 Oct 11. Erratum in: Lancet HIV. 2022 Dec;9(12):e822. PMID: 36240834; PMCID: PMC9667733.

  • Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia JV, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE for the BRIEF TB/A5279 Study Team. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380:1001-1011. DOI: 10.1056/NEJMoa1806808.

  • Tornheim JA, Madugundu AK, Paradkar M, Fukutani KF, Queiroz ATL, Gupte N, Gupte AN, Kinikar A, Kulkarni V, Balasubramanian U, Sreenivasamurthy S, Raja R, Pradhan N, Shivakumar SVBY, Valvi C, Hanna LE, Andrade BB, Mave V, Pandey A, Gupta A; CTRIUMPh RePORT India Study Team. Transcriptomic Profiles of Confirmed Pediatric Tuberculosis Patients and Household Contacts Identifies Active Tuberculosis, Infection, and Treatment Response Among Indian Children. J Infect Dis. 2020 Apr 27;221(10):1647-1658. doi: 10.1093/infdis/jiz639. PMID: 31796955

  • Gupte AN, Kumar P, Araújo-Pereira M, Kulkarni V, Paradkar M, Pradhan N, Menon P, Padmapriyadarsini C, Hanna LE, Yogendra Shivakumar SVB, Rockwood N, Du Bruyn E, Karyakarte R, Gaikwad S, Bollinger R, Golub J, Gupte N, Viswanathan V, Wilkinson RJ, Mave V, Babu S, Kornfeld H, Andrade BB, Gupta A. Baseline IL-6 is a biomarker for unfavourable tuberculosis treatment outcomes: a multisite discovery and validation study. Eur Respir J. 2022 Apr 21;59(4):2100905. doi: 10.1183/13993003.00905-2021. PMID: 34711538; PMCID: PMC7612881. 

A5300B/I2003B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx)
HATHI: RCT for Alcohol Reduction Among People with TB and HIV in India
IMPAACT 1078: Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High TB Incidence Settings
Regional Prospective Observational Research for Tuberculosis (RePORT) India
Impact of Immune Changes of Pregnancy on Tuberculosis
C-TRIUMPh: Cohort for TB Research by the Indo-US Medical Partnership
CDC SHEPHERD Study: AMR in India
Hinduja-Hopkins TB Research Observational Clinical Database
Regional Prospective Observational Research for Tuberculosis (RePORT) International (RICC)
Impact of Diabetes on TB Treatment Outcomes: Tuberculosis-Diabetes Cohort
Optimizing Treatment to Improve TB Meningitis Outcomes in Children
Residual Respiratory Impairment Following Pulmonary Tuberculosis
COVID analyses: JH CROWN Registry
TB Free Schools Initiative